Quantitative Optical Coherence Tomography Angiography Biomarkers for Alport Syndrome

Ophthalmologica. 2022;245(1):41-48. doi: 10.1159/000519242. Epub 2021 Sep 1.

Abstract

Purpose: The aim of this study was to evaluate microvascular abnormalities of patients with Alport syndrome (AS) using optical coherence tomography angiography (OCT-A) quantitative biomarkers.

Methods: This was cross sectional, prospective evaluation of consecutive patients with AS and healthy subjects. AS diagnosis was performed by the genetic test. All participants underwent a retinal vasculature evaluation by spectral-domain optical coherence tomography (SD-OCT) and OCT-A of the macula. Quantitative analysis included whole vascular density, foveal avascular zone area, fractal dimension (FD), and lacunarity (LAC).

Results: Ninety-four eyes were included in this study, 45 eyes from patients with AS and 49 eyes from healthy subjects. The pathogenic mutation in the COL4A5 gene on the chromosome X was found in 14 patients; the pathogenic autosomal recessive mutations in the COL4A3 gene were found in 9 patients. Quantitative evaluation demonstrated a significant difference between AS and healthy subjects on LAC of the superficial capillary plexus and deep capillary plexus (DCP) (p < 0.001 and p < 0.001, respectively) and on FD in the DCP (p < 0.001).

Conclusion: The DCP Alport patients have a higher vessel nonuniformity than DCP of healthy subjects. We hypothesize that endothelial cell lesion in the setting of low resistance at the DCP circuit could lead to long-term structural disorganization.

Keywords: Alport syndrome; Optical coherence tomography angiography; Quantitative biomarkers; Spectral-domain optical coherence tomography.

MeSH terms

  • Biomarkers
  • Cross-Sectional Studies
  • Fluorescein Angiography / methods
  • Humans
  • Macula Lutea*
  • Nephritis, Hereditary* / diagnosis
  • Nephritis, Hereditary* / genetics
  • Nephritis, Hereditary* / pathology
  • Retinal Vessels / pathology
  • Tomography, Optical Coherence / methods
  • Visual Acuity

Substances

  • Biomarkers